切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2026, Vol. 19 ›› Issue (04) : 600 -606. doi: 10.3877/cma.j.issn.1674-6902.2026.04.011

论著

外周血炎症指数预测148例局部晚期NSCLC免疫化疗后MPR的临床意义
丁海斌1, 刘爽1, 乔丹1, 李新涛1, 陈艳妮2,†(), 程蒿3, 刘佳3   
  1. 1710000　西安，陕西省肿瘤医院肿瘤内二科
    2725000　陕西，安康市中心医院肿瘤内科
    3710000　西安，陕西省肿瘤医院病理科
  • 收稿日期:2026-03-25 出版日期:2026-08-25
  • 通信作者: 陈艳妮
  • 基金资助:
    陕西省中医管理局中医药科研课题(LCPT037)

Clinical significance of peripheral blood inflammation index in predicting major pathological response after immunochemotherapy in 148 cases with locally advanced nonsmall cell lung cancer

Haibin Ding1, Shuang Liu1, Dan Qiao1, Xintao Li1, Yanni Chen2,†(), Hao Cheng3, Jia Liu3   

  1. 1Department of Oncology Ⅱ, Shaanxi Cancer Hospital, Xi'an 710000, China
    2Department of Medical Oncology, Ankang Central Hospital, Ankang, 725000, China
    3Department of Pathology, Shaanxi Provincial Cancer Hospital, Xi′an 71000, China
  • Received:2026-03-25 Published:2026-08-25
  • Corresponding author: Yanni Chen
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

丁海斌, 刘爽, 乔丹, 李新涛, 陈艳妮, 程蒿, 刘佳. 外周血炎症指数预测148例局部晚期NSCLC免疫化疗后MPR的临床意义[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 600-606.

Haibin Ding, Shuang Liu, Dan Qiao, Xintao Li, Yanni Chen, Hao Cheng, Jia Liu. Clinical significance of peripheral blood inflammation index in predicting major pathological response after immunochemotherapy in 148 cases with locally advanced nonsmall cell lung cancer[J/OL]. Chinese Journal of Lung Diseases(Electronic Edition), 2026, 19(04): 600-606.

目的

探讨外周血炎症指标对局部晚期非小细胞肺癌(nonsmall cell lung cancer, NSCLC)患者免疫联合化疗后主要病理缓解(major pathological response, MPR)的预测意义。

方法

选择2022年2月至2025年1月我院收治的接受新辅助免疫联合化疗局部晚期NSCLC患者104例，依据术后病理结果分为MPR为观察组63例与无MPR为对照组41例。收集患者临床资料、治疗前后中性粒细胞与淋巴细胞计数比值(neutrophiltolymphocyte ratio, NLR)、血小板与淋巴细胞计数比值(platelettolymphocyte ratio, PLR)、全身免疫炎症指数(systemic immuneinflammation, SII)，预后营养指数(prognostic nutritional index, PNI)，计算变化值(Δ＝治疗后－治疗前)。采用LASSO回归筛选变量，多因素Logistic回归确定MPR影响因素并构建列线图；通过Kaplan-Meier法结合Log-Rank检验分析动态炎症评分与EFS的关联。

结果

观察组治疗后ΔNLR[－0.65(－1.71，－0.27)比0.58(0.22，1.94)，Z＝－5.053，P<0.001]、ΔPLR[－48.13(－102.80，－12.83)比26.22(－16.87，60.70)，Z＝－4.660，P<0.001]、ΔSII[－225.54(－411.09，－83.77)比380.83(104.52，538.33)，Z＝－5.768，P<0.001]低于对照组，ΔPNI[0.98(－1.80，3.71)比－1.63(－7.15，0.79)，Z＝－5.236，P<0.001]高于对照组。多因素Logistic回归显示，病理亚型(腺癌比鳞癌：OR＝0.127，95%CI：0.021~0.769，P＝0.025)、组织学分化(低分化比中分化：OR＝0.022，95%CI：0.002~0.294，P＝0.004)、ΔNLR(OR＝0.518，95%CI：0.299~0.898，P＝0.019)、ΔSII(OR＝0.996，95%CI：0.993~0.998，P＝0.002)、ΔPNI(OR＝1.514，95%CI：1.146~2.001，P＝0.004)为MPR影响因素。列线图模型预测MPR的AUC为0.95(95%CI：0.91~0.99)，Hosmer-Lemeshow检验显示模型拟合良好(χ2＝6.610，P＝0.579)，决策曲线显示0.10~0.92风险阈值区间内净临床获益高。以动态炎症评分中位值0.76为截点，低评分组(52例)中位EFS为22个月，短于高评分组52例36个月(Log-Rank χ2＝30.989，P<0.001)。

结论

新辅助免疫联合化疗前后ΔNLR、ΔSII、ΔPNI是局部晚期NSCLC患者术后MPR的预测标志物；联合病理亚型、组织学分化程度构建列线图模型区分效能、校准度及临床净获益优异，可术前预测新辅助免疫联合化疗的病理应答，为患者远期复发风险分层提供参考。

关键词: 非小细胞肺癌, 局部晚期, 外周血炎症指数, 动态预测, 新辅助免疫化疗, 主要病理缓解
Objective

To investigate the predictive value of peripheral blood inflammatory markers for major pathological response (MPR) in patients with locally advanced nonsmall cell lung cancer (NSCLC) receiving neoadjuvant immunochemotherapy.

Methods

A total of 104 patients with locally advanced NSCLC who received neoadjuvant immunochemotherapy at our hospital from February 2022 to January 2025 were retrospectively enrolled. Based on postoperative pathological findings, MPR were divided into the observation group (63 cases) and non MPR were the control group (41 cases). Clinical data, as well as pre and posttreatment neutrophiltolymphocyte ratio (NLR), platelettolymphocyte ratio (PLR), systemic immuneinflammation index (SII), and prognostic nutritional index (PNI), were collected. The change values (Δ=posttreatment-pretreatment) were calculated. LASSO regression was used for variable selection, and multivariate Logistic regression was performed to identify independent factors associated with MPR and to construct a nomogram. The association between dynamic inflammation score and eventfree survival (EFS) was analyzed using the KaplanMeier method with the Logrank test.

Results

After treatment, the observation group showed significantly lower ΔNLR[-0.65(-1.71, -0.27) vs. 0.58 (0.22, 1.94), Z= -5.053, P<0.001], ΔPLR[-48.13 (-102.80, -12.83) vs. 26.22 (-16.87, 60.70), Z=-4.660, P<0.001], and ΔSII[-225.54 (-411.09, -83.77) vs. 380.83 (104.52, 538.33), Z=-5.768, P<0.001], and significantly higher ΔPNI[0.98(-1.80, 3.71) vs. -1.63 (-7.15, 0.79), Z=-5.236, P<0.001] than the control group. Multivariate Logistic regression revealed that pathological subtype (adenocarcinoma vs. squamous cell carcinoma: OR=0.127, 95%CI: 0.021~0.769, P=0.025), histological differentiation (poorly differentiated vs. moderately differentiated: OR=0.022, 95%CI: 0.002~0.294, P=0.004), ΔNLR(OR=0.518, 95%CI: 0.299~0.898, P=0.019), ΔSII (OR=0.996, 95%CI: 0.993~0.998, P=0.002), and ΔPNI (OR=1.514, 95%CI: 1.146~2.001, P=0.004) were independent factors for MPR. The nomogram model yielded an AUC of 0.95 (95%CI: 0.91~0.99) for predicting MPR. The HosmerLemeshow test indicated good model calibration (χ2=6.610, P=0.579), and the decision curve analysis demonstrated a high net clinical benefit within the risk threshold range of 0.10~0.92. Using the median dynamic inflammation score of 0.76 as the cutoff, the lowscore group (52 cases) had a significantly shorter median EFS of 22 months compared with 36 months in the highscore group (52 cases) (Logrank χ2= 30.989, P<0.001).

Conclusions

Dynamic changes in ΔNLR, ΔSII, and ΔPNI before and after neoadjuvant immunochemotherapy are predictive biomarkers for postoperative MPR in patients with locally advanced NSCLC. The nomogram combining these markers with pathological subtype and histological differentiation exhibits excellent discriminative ability, calibration, and clinical net benefit, which may help preoperatively predict pathological response to neoadjuvant immunochemotherapy and provide a reference for longterm recurrence risk stratification.

Key words: Non-small cell lung cancer, Locally advanced, Peripheral blood inflammation index, Dynamic prediction, Neoadjuvant immunochemotherapy, Major pathological response
表1 两组局部晚期NSCLC患者临床资料结果
临床资料 对照组(n＝41) 观察组(n＝63) t/χ2/Z值 P值
淋巴结清扫数[n(%)]     0.599 0.439
<10个 24(58.54) 32(50.79)    
≥10个 17(41.46) 31(49.21)    
术后辅助化疗[n(%)] 21(51.22) 30(47.62) 0.129 0.720
术后辅助放疗[n(%)] 7(17.07) 8(12.70) 0.385 0.535
基线实验室指标[M50(P25，P75)]        
癌胚抗原(ng/ml) 4.22(2.00，16.07) 6.63(2.21，18.76) －0.193 0.847
细胞角蛋白19片段(ng/ml) 2.97(2.07，4.91) 3.79(2.06，8.06) －0.831 0.406
白蛋白(g/L) 42.30(35.10，47.60) 43.85(38.20，47.03) －1.504 0.133
血红蛋白(g/L) 113.50(95.00，123.75) 116.00(102.50，128.00) －1.657 0.097
白细胞计数(×109/L) 1.29(1.03，1.78) 1.43(0.97，1.76) －1.397 0.162
中性粒细胞计数(×109/L) 3.39(2.42，5.00) 3.84(2.32，4.94) －0.336 0.737
嗜酸性粒细胞计数(×109/L) 0.08(0.04，0.13) 0.10(0.05，0.20) －1.142 0.253
单核细胞计数(×109/L) 0.53(0.48，0.65) 0.48(0.36，0.76) －0.642 0.521
血小板计数(×109/L) 231.00(189.50，292.75) 230.50(180.00，310.25) －0.296 0.767
NLR 2.93(1.92，3.83) 2.43(1.60，3.28) －1.630 0.103
NER 42.19(22.20，83.85) 36.80(14.91，130.44) －0.283 0.777
PLR 182.22(112.13，261.88) 174.41(117.35，233.13) －1.497 0.134
LMR 2.38(1.92，3.51) 2.46(2.01，3.45) －1.314 0.189
SII 380.83(104.52，538.33) 434.41(203.49，894.28) －1.094 0.274
PNI 51.33(40.70，53.75) 51.73(45.01，54.28) －1.384 0.166
表2 两组局部晚期NSCLC患者肿瘤分期及治疗
临床资料 对照组(n＝41) 观察组(n＝63) t/χ2/Z值 P值
病变侧[n(%)]     0.109 0.741
左肺 33(80.49) 49(77.78)    
右肺 8(19.51) 14(22.22)    
分化[n(%)]     4.308 0.038
中分化 10(24.39) 28(44.44)    
低分化 31(75.61) 35(55.56)    
TNM分期[n(%)]     4.303 0.038
ⅢA 13(31.71) 33(52.38)    
ⅢB 28(68.29) 30(47.62)    
T分期[n(%)]     0.406 0.524
T1~2 15(36.59) 27(42.86)    
T3~4 26(63.41) 36(57.14)    
N分期[n(%)]     2.716 0.099
N1~2 16(39.02) 35(55.56)    
N3 25(60.98) 28(44.44)    
PD-1抑制剂[n(%)]     0.634 0.889
Pembrolizumab 11(26.83) 19(30.16)    
Sintilimab 16(39.02) 26(41.27)    
Tislelizumab 9(21.95) 10(15.87)    
Camrelizumab 5(12.20) 8(12.70)    
铂类药物[n(%)]     0.045 0.831
顺铂 23(56.10) 34(53.97)    
卡铂 18(43.90) 29(46.03)    
化疗骨架药物[n(%)]     0.533 0.466
白蛋白结合型紫杉醇 27(65.85) 37(58.73)    
培美曲塞二钠 14(34.15) 26(41.27)    
图1 局部晚期NSCLC患者影像学表现。图A为治疗前胸部CT肺窗轴位图像，可见右肺原发占位病灶基线形态及肺内周边结构；图B为新辅助免疫化疗后复查胸部CT肺窗轴位图像，对比可见原发病灶形态、大小变化，提示新辅助免疫化疗后肿瘤影像学应答改变；图C为治疗前胸部CT纵隔窗轴位图像，显示右肺原发病灶；图D为新辅助免疫化疗后复查胸部CT纵隔窗轴位，对比可见右肺原发病灶体积改变
图2 局部晚期NSCLC患者组织病理学图。图A为右中叶肺鳞状细胞癌Ⅱ~Ⅲ级；图B为肺腺癌Ⅱ~Ⅲ级伴局灶鳞状分化；图C为转移性低分化肺腺癌；图D为肺低分化鳞状细胞癌
表3 两组局部晚期NSCLC患者治疗前后炎症指数变化
炎症指数 对照组(n＝41) 观察组(n＝63) Z值 P值
ΔNLR 0.58(0.22，1.94) －0.65(－1.71，－0.27) －5.053 0.001
ΔNER 6.50(－13.49，42.18) －7.78(－74.70，14.85) －1.683 0.092
ΔPLR 26.22(－16.87，60.70) －48.13(－102.80，－12.83) －4.660 0.001
ΔLMR －0.33(－0.94，－0.06) 0.04(－0.89，0.98) －1.001 0.317
ΔSII 78.35(－59.62，317.56) －225.54(－411.09，－83.77) －5.768 0.001
ΔPNI －1.63(－7.15，0.79) 0.98(－1.80，3.71) －5.236 0.001
表4 Logistic回归分析局部晚期NSCLC患者MPR的影响因素
影响因素 b SE(b) Walds值 OR(95%CI) P值
病理亚型-腺癌 －2.067 0.920 5.044 0.127(0.021~0.769) 0.025
组织学分化-低分化 －3.814 1.321 8.329 0.022(0.002~0.294) 0.004
ΔNLR －0.657 0.280 5.494 0.518(0.299~0.898) 0.019
ΔPLR －0.004 0.006 0.422 0.996(0.984~1.008) 0.516
ΔSII －0.004 0.001 9.359 0.996(0.993~0.998) 0.002
ΔPNI 0.415 0.142 8.512 1.514(1.146~2.001) 0.004
图3 局部晚期NSCLC患者新辅助免疫化疗后MPR预测列线图
1
Luo G, Zhang Y, Rumgay H, et al. Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study[J]. Lancet Respir Med, 2025, 13(4): 348-363.
2
Mina SA, Shanshal M, Leventakos K, et al. Emerging targeted therapies in non-small-cell lung cancer (NSCLC)[J]. Cancers, 2025, 17(3): 353.
3
Xu Y, Ma D, Qin Y, et al. Prognostic significance of pathological response and lymph node status in neoadjuvant immunotherapy for potentially resectable non-small cell lung cancer[J]. Ann Med, 2025, 57(1): 2453825.
4
Akinboro O, Drezner N, Amatya A, et al. US food and drug administration approval summary: nivolumab plus platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non-small-cell lung cancer[J]. J Clin Oncol, 2023, 41(17): 3249-3259.
5
蔡晓婷，刘颖. 非小细胞肺癌新辅助免疫治疗的影像评估现状及研究进展[J]. 中华放射学杂志，2025, 59(7): 833-837.
6
Wang H, Niu X, Jin Z, et al. Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities[J]. J Exper Clin Cancer Res, 2025, 44(1): 250.
7
蒋微，池传珍，王伟，等. 外周血炎症指标对晚期非小细胞肺癌免疫治疗疗效的预测价值[J]. 河北医药，2024, 46(18): 2853-2857.
8
Xu W, Liu X, Yan C, et al. The prognostic value and model construction of inflammatory markers for patients with non-small cell lung cancer[J]. Sci Rep, 2024, 14(1): 7568.
9
Xie Y, Yu Q, Zhu Y, et al. The value of peripheral blood inflammation markers in risk assessment and prediction of lung cancer[J]. Future Sci OA, 2025, 11(1): 2476870.
10
杨燕，顾国民. 系统性免疫炎症指数对晚期非小细胞肺癌患者预后的预测价值[J]. 中国实验诊断学，2024, 27(9): 1041-1044.
11
Saeed R, McSorley S, Cascales A, et al. The prognostic/ predictive value of the systematic inflammatory response in patients receiving immunotherapy for non-small cell lung cancer: a systematic review and meta-analysis [J]. BMC Cancer, 2025, 25(1): 994.
12
Geng Z, Hu Y, Zhou S, et al. Prediction of tumor-infiltrating lymphocytes through habitat radiomics and exploration of response mechanisms in neoadjuvant immunochemotherapy-treated lung cancer[J]. Cancer Immunol Immunother, 2026, 75(2): 42.
13
Xu F, Zhu H, Xiong D, et al. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study[J]. Thorac Cancer, 2024, 15(2): 172-181.
14
Sorin M, Prosty C, Ghaleb L, et al. Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and Meta-analysis[J]. JAMA Oncol, 2024, 10(5): 621-633.
15
Lei Y, Cao C, Tang R, et al. Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids[J]. BMC Cancer, 2025, 25(1): 664.
16
Bi ZK, Xu Y, Guo L, et al. Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease[J]. Zhonghua Yi Xue Za Zhi, 2024, 104(18): 1601-1609.
17
Liao S, Sun H, Lu H, et al. Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy[J]. BMC Cancer, 2025, 25(1): 697.
18
Knetki-Wróblewska M, Grzywna A, Krawczyk P, et al. Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in second-line immunotherapy for patients with non-small cell lung cancer[J]. Transl Lung Cancer Res, 2025, 14(3): 749-760.
19
Li C, Wu J, Jiang L, et al. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study[J]. Cancer Immunol Immunother, 2023, 72(3): 783-794.
20
Zhang Y, Yan N, Feng Y, et al. Inflammatory markers predict efficacy of immunotherapy in advanced non-small cell lung cancer: a preliminary exploratory study[J]. Discov Oncol, 2025, 16(1): 8.
21
Huai Q, Luo C, Song P, et al. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy[J]. Cancer Sci, 2023, 114(12): 4484-4498.
22
Liu J, Liu J, Chen H, et al. Prognostic value of combined nutritional and inflammatory markers in NSCLC patients receiving ICIs[J]. Discov Oncol, 2025, 16(1): 571.
23
刘小丽，罗倩，种玉婷，等. 抗血管生成药物联合PD-1单抗治疗NSCLC的疗效及对T淋巴细胞亚群的影响[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(4): 510-515.
24
Zhang F, Xia Y, Su J, et al. Neutrophil diversity and function in health and disease[J]. Signal Transduct Target Therapy, 2024, 9(1): 343.
25
Ahmed H, Mahmud AR, Faijanur-Rob-Siddiquee M, et al. Role of T cells in cancer immunotherapy: Opportunities and challenges[J]. Cancer Pathogen Therapy, 2023, 1(2): 116-126.
26
Gebhardt T, Park SL, Parish IA. Stem-like exhausted and memory CD8＋ T cells in cancer[J]. Nat Rev Cancer, 2023, 23(11): 780-798.
27
Liao K, Zhang X, Liu J, et al. The role of platelets in the regulation of tumor growth and metastasis: the mechanisms and targeted therapy[J]. Med Comm, 2023, 4(5): e350.
28
孟芸畅，许可，宋勇. 新辅助免疫治疗在可切除非小细胞肺癌中的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(5): 734-738.
29
Lei W, Wang W, Qin S, et al. Predictive value of inflammation and nutritional index in immunotherapy for stage Ⅳ non-small cell lung cancer and model construction[J]. Sci Rep, 2024, 14(1): 17511.
[1] 李春艳, 郎广碧, 周亚, 陈晓龙, 胡明冬. 胸部SMARCA4缺失型非小细胞肺癌与SMARCA4缺失型未分化肿瘤的组织病理学特征、影像学表现及预后分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 534-541.
[2] 刘慧, 赵燕霞, 汪海涛, 魏肖慧, 魏雪梅. CT肿瘤内部异质性对NSCLC患者免疫治疗反应性的预测价值[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 560-565.
[3] 黄丛秀, 王少军, 郁志龙, 苏乌云, 刘彩霞, 孙晓革. 局部晚期非小细胞肺癌放疗联合免疫治疗并发治疗相关性肺炎的危险因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 566-571.
[4] 李洋, 陈雨欣, 高娜, 李继霞, 米晶晶, 贺元, 曹鸿鑫. 不同剂量贝伐珠单抗联合培美曲塞及铂类药物治疗晚期NSCLC疗效与安全性倾向性匹配分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(04): 578-585.
[5] 陈希, 范海华, 倪婷婷, 宋丽, 邵丽丽. cfDNA、NLR及PD-L1联合检测对42例非小细胞肺癌患者免疫治疗疗效的预测意义[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(03): 405-410.
[6] 毛燕青, 张妤, 付婷, 王翎, 王娟, 梁容瑞. Revolution CT能谱成像技术联合p53、GAGE7表达在非小细胞肺癌诊断中临床意义[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(03): 431-436.
[7] 许猛军, 殷海涛, 史凌云, 马高磊, 张英楠, 郭雯雯, 王曼, 张静雅, 刘枫, 陈远远. 不同剂量调强放疗对144例局部晚期非小细胞肺癌患者的疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(03): 476-479.
[8] 乔伟, 周前鑫, 苏悦, 马源, 赵沙. 动态免疫特征预测晚期非小细胞肺癌免疫疗法治疗肺孢子菌感染风险的研究[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(02): 181-188.
[9] 沈梦熠, 陈佳妍, 陈玥莹, 王振, 许春伟, 王栋, 吕镗烽. ALK阳性非小细胞肺癌患者靶向治疗失败后的疾病进展模式分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(02): 189-196.
[10] 姬雅君, 闫立华, 张庚, 孙文波, 杨丽娜. 布托啡诺复合瑞马唑仑用于非小细胞肺癌单孔胸腔镜肺叶切除术中的临床效果研究[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(02): 262-268.
[11] 刘佳铭, 文健, 孙晓容, 钟瑶, 张雯. 慢性阻塞性肺疾病合并肺癌免疫检查点抑制剂相关重症皮疹一例[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(02): 353-355.
[12] 胡佳, 任甜甜, 吴刘萍, 秦雯, 罗均, 蔡淑昕, 朱琴. 87例非小细胞肺癌患者胸腔镜术后疼痛影响因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(01): 112-116.
[13] 王辉, 汪海涛, 张建庆. 立体定向放射治疗后使用替雷利珠单抗治疗112例mNSCLC患者的疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(01): 124-131.
[14] 余绍斌, 康明强. ⅠA3期非小细胞肺癌预后差异及治疗策略研究进展[J/OL]. 中华胸部外科电子杂志, 2026, 13(02): 132-139.
[15] 王炜东, 张兰军. ALK阳性非小细胞肺癌术后辅助靶向治疗进展——QEELIN研究解读[J/OL]. 中华胸部外科电子杂志, 2026, 13(01): 74-82.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？